“Budget impact analysis of the use of daclatasvir in Italy for the treatment of Hepatitis C Virus (HCV) genotype 3 patients” (2016) Farmeconomia. Health Economics and Therapeutic Pathways, 17(1), pp. 7–12. doi:10.7175/fe.v17i1.1225.